Tirzepatide MTD Demonstrates Cost-Effectiveness Versus Semaglutide MTD in Obesity Simulation Modeling Study
Tirzepatide Saves Money and Health Over Semaglutide
This simulation modeling study using Phase-3 trial data evaluated tirzepatide versus semaglutide in individuals with obesity or overweight w…
Imagine standing in a doctor's office, facing a choice between two powerful weight-loss medicines.
Narrative review compares tirzepatide and semaglutide for obesity and type 2 diabetes outcomes
New Obesity Drug Shows Stronger Weight Loss Than Popular Option
This narrative review evaluates tirzepatide versus semaglutide in individuals with obesity or type 2 diabetes mellitus.
This review shows that tirzepatide outperforms semaglutide for weight and blood sugar, but semaglutide currently has stronger proof for prot…
Review of new-user target trial emulation comparing semaglutide and SGLT2i in U.S. Veterans with type 2 diabetes
Semaglutide Does Not Raise Suicide Risk, Study Finds
This active-comparator, new-user target trial emulation review synthesizes data from 102,361 U.S.
A large new study finds that semaglutide does not increase suicide risk compared to other diabetes drugs, easing fears for millions of patie…
Monitoring report on US GLP-1 RA prescribing trends shows increased oral semaglutide use
Why are so many people getting new diabetes and weight-loss drugs?
This monitoring report analyzes real-world US electronic health record data from Truveta on GLP-1 RA prescribing.
Prescriptions for diabetes and weight-loss drugs jumped sharply in the US after a new oral pill was approved, with first-time use rising ove…
Observational study links semaglutide dose and weight loss to lower liver disease risk
Study links semaglutide use to lower risk of several liver conditions in patients with liver disease
This observational study from a real-world federated EHR network analyzed 6,734 patients with liver disease.
Higher semaglutide doses and greater weight loss were linked to lower risks of steatohepatitis, alcoholic liver disease, and death in patien…
Tirzepatide shows greater lean body mass loss than semaglutide in first-episode GLP-1RA users with type 2 diabetes
One Weight-Loss Drug Trims More Muscle Than the Other — Here's Why
An observational study of 670,422 first-episode GLP-1RA users with type 2 diabetes found tirzepatide was associated with greater relative le…
Losing weight with a popular injection drug is not all equal — one drug may chip away at your muscle more than the other, which matters grea…
Orforglipron shows superior HbA1c reduction versus oral semaglutide in adults with type 2 diabetes on metformin
A New Diabetes Pill Takes On Ozempic's Oral Cousin
A phase 3 RCT of 1698 adults with type 2 diabetes inadequately controlled on metformin found that once-daily oral orforglipron (12 mg or 36 …
A new once-daily diabetes pill called orforglipron lowered blood sugar better than oral semaglutide in a major head-to-head trial, but at th…
Semaglutide dose linked to lower mortality and cardiovascular risk in patients with baseline CVD
Why Ozempic's Heart Benefits May Have Nothing to Do With Weight Loss
An observational study of 47,199 patients with baseline cardiovascular disease in a U.S.
A massive real-world study of over 47,000 heart patients suggests that semaglutide may protect the heart through direct biological effects —…
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
A Clear Winner Emerges for Diabetes Patients with Kidney Disease
This network meta-analysis evaluated novel antidiabetic drugs, including SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, i…
For millions managing both diabetes and kidney disease, new research clarifies which medications offer the best protection for their heart a…
Oral semaglutide reduces composite heart failure outcomes in patients with type 2 diabetes and heart failure history
A Common Diabetes Pill May Also Protect Your Heart From Failure
This secondary analysis of a phase 3b randomized clinical trial evaluated once-daily oral semaglutide versus placebo in 9,650 participants w…
For millions living with type 2 diabetes and a struggling heart, a medication they might already be taking could offer a powerful, two-in-on…
Efruxifermin shows superior fibrosis regression in compensated MASH cirrhosis compared to placebo in a network meta-analysis
New drug ranking shows one treatment stands out for advanced fatty liver scarring
This network meta-analysis evaluated histological efficacy in patients with biopsy-proven compensated metabolic dysfunction-associated steat…
Efruxifermin is the only drug proven to shrink advanced liver scarring without worsening the disease, ranking first among new treatments for…
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
Do heart benefits from diabetes drugs work equally well across different races?
A meta-analysis of 74,703 adults with type 2 diabetes or overweight/obesity found GLP-1RAs reduced MACE risk versus placebo.
Diabetes drugs protect hearts in Asian and White adults, but the benefit for Black adults remains unclear due to small study numbers.